BUND FINANCE

BUND FINANCE › Stocks › INSM

Insmed Incorporated (INSM)

NASDAQ · Stock price, chart and technical analysis

US$119.80-2.06 (-1.69%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$121.86
OpenUS$121.94
Day rangeUS$118.83 – US$122.42
52-week rangeUS$90.39 – US$212.75
Market capUS$26.28B
Volume1.94M
50-day averageUS$110.69
200-day averageUS$122.83
Beta0.81

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$188.5MUS$245.4MUS$305.2MUS$363.7MUS$606.4M
Net income−US$434.7M−US$481.5M−US$749.6M−US$913.8M−US$1.3B
EPS (diluted)-3.88-3.91-5.34-5.57-6.41
Gross margin76.6%77.5%78.5%76.4%79.4%
Operating margin-199.0%-186.4%-232.5%-241.5%-194.0%
Net margin-230.6%-196.3%-245.6%-251.2%-210.5%
Free cash flow−US$370.6M−US$410.3M−US$549.5M−US$705.8M−US$967.6M
Total debtUS$612.3MUS$1.2BUS$1.2BUS$1.3BUS$768.2M
CashUS$716.8MUS$1.1BUS$482.4MUS$555.0MUS$510.4M

Compound annual growth: revenue 33.9% · net income — (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E——27.1x
EV / EBITDA——16.5x
Operating margin-35.6%—3.6%
Net margin-39.9%—-0.0%
Debt / equity2.07—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Insmed Incorporated

SectorHealthcare
IndustryBiotechnology
CountryUS
CEOWilliam H. Lewis
Employees1,664
IPO date2000-06-01

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation…

www.insmed.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice